FORTE Healthcare Limited announces launch of Cryptisel 0.5mg/ml oral solution for calves to the market in the UK and Ireland.
Cryptisel contains the active ingredient halofuginone – a potent anticoccidial – used for the prevention and reduction of diarrhoea caused by Cryptosporidium parvum in calves.
Cryptisel is used to reduce oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem. After the presence of the causal organism has been established, Cryptisel is used in all new-born calves to break the cycle of transmission and multiplication on-farm.
Dr John Henderson, Large Animal Product Manager with Forte Healthcare Ltd said, “Cryptisel will be a very useful medicine in the control of the most commonly-identified scour pathogen in the UK and Ireland. Used alongside the calf-rearing cornerstones of good colostrum management, hygiene, and biosecurity, Cryptisel will reduce production of Cryptosporidium oocysts and help limit spread of the disease among susceptible calves.”
Cryptisel is a prescription medication and is available in 490ml and 980ml bottles. Both sizes come with a metered dosing pump for convenient administration.
Cryptisel is the latest addition to Forte Healthcare’s high quality range of generics.